Compare Amylx Pharmaceuticals Inc (AMLX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Banco Santander SA trades at $14.88 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 80.2× Amylx Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SAN | |
|---|---|---|
Market Cap | $2.64B | $211.63B |
Sector | Health | Financials |
52-Week High | $24.19 | $14.71 |
52-Week Low | $7.82 | $9.37 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 1.89% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
